N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
Deak, H.L., Newcomb, J.R., Nunes, J.J., Boucher, C., Cheng, A.C., DiMauro, E.F., Epstein, L.F., Gallant, P., Hodous, B.L., Huang, X., Lee, J.H., Patel, V.F., Schneider, S., Turci, S.M., Zhu, X.(2008) Bioorg Med Chem Lett 18: 1172-1176
- PubMed: 18083554 
- DOI: https://doi.org/10.1016/j.bmcl.2007.11.123
- Primary Citation of Related Structures:  
3B2W - PubMed Abstract: 
N-3-(Phenylcarbamoyl)arylpyrimidine-5-carboxamides are a novel class of selective Lck inhibitors. This series of compounds derives its selectivity from a hydrogen bond with the gatekeeper Thr316 of the enzyme. X-ray co-crystal structural data, structure-activity relationships, and the synthesis of these inhibitors are reported herein.
Organizational Affiliation: 
Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA. holly.deak@amgen.com